

IFN

BUCKET NO.: JANS-0042

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Frans E. Janssens, et al.

Application No.: 10/817,472

Filing Date: April 2, 2004

For: RESPIRATORY SYNCYTIAL VIRUS REPLICATION

Confirmation No.:

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

DATE OF DEPOSIT: May 27, 2004

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Wendy A. Choi

TYPED NAME: Wendy A. Choi
REGISTRATION NO.: 36,697

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

☐ In accordance with § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached;

or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

- ☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
- ☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith
- ☐ Copies of references listed on the attached Form PTO 1449 are not required to be submitted pursuant to the June 30, 2003 recent revisions to 37 CFR § 1.98(a)(2)(i).


EXCEPT THAT:

- ☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☒ In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application:
- ☒ Copies of references **1 thru 28** listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. **10/019,380**, filed **December 27, 2001**.


Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

There are no listed references which are not in the English language.

Date: May 27, 2004


Wendy A. Choi
Registration No. 36,697

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439



| | | | |
|---|---|---|--------------------------------------|
| Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office | | Docket No. JANS-0042 | Application No. 10/817,472 |
| | | Applicant Frans E. Janssens, et al. | |
| | | Filing Date April 2, 2004 | Group Not Yet Assigned |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | |
| | 1 | Akula, M. R. et al., "An Improved Synthesis of 3-Phenyl-and 3-Methoxyquinaldine," <i>Org. Prep. Proced. Int.</i> , 1991 , 23, pp. 386-387 | |
| | 2 | Cerè, V. et al., "Catalytic Hydrogenation of Benzo[2.1.3]Oxadiazoles," <i>Tetrahedron</i> , 1972 , 28, 3271-3276 | |
| | 3 | Chiba, T. et al., "Inhibitory Effect of Pyridobenzazoles on Virus Replication in vitro," <i>Biol Pharm Bull</i> , 1995 , 18(8), 1081-1083 | |
| | 4 | Goodman and Gilman, "Biotransformation of Drugs," in <i>The Pharmacological Basis of Therapeutics</i> , 8 th ed., McGraw-Hill, Int. Ed. 1992 , 13-15 | |
| | 5 | Greene, T. et al., <i>Protective Groups in Organic Synthesis</i> , John Wiley & Sons Inc., 1991 , Chapter 7 | |
| | 6 | Lindström, S. et al., "Synthesis of the Mutagenic 2-Amino-1,6-Dimethyl-Imidazo[4,5- <i>b</i>]Pyridine (1,6-DMIP) and Five of Its Isomers," <i>Heterocycles</i> , 1994 , 38(3), 529-540 | |
| | 7 | Richardson, Jr. et al. "Study of the Synthesis and Chemistry of the 5,6-Dihydroimidazo[<i>ij</i>]quinoline Series," <i>J. Org. Chem.</i> , 1960 , 25, 1138-1147 | |
| | 8 | Tidwell, R. et al., "Aromatic Amidines: Comparison of Their Ability to Block Respiratory Syncytial Virus Induced Cell Fusion and to Inhibit Plasmin, Urokinase, Thrombin, and Trypsin," <i>J Med Chem</i> , 1983 , 26, 294-298 | |
| | 9 | Wyde et al., "CL387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture and in cotton rats," <i>Antivirus Research</i> , 1998 , 38, 31-42 | |
| | | | |
| EXAMINER | | DATE CONSIDERED | |

Form PTO-1449 Modified

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce
Patent and Trademark Office

Docket No.
JANS-0042

Application No.
10/817,472

Applicant
Frans E. Janssens, et al.

Filing Date
April 2, 2004

Group
Not Yet Assigned

U. S. PATENT DOCUMENTS

| Examiner Initial | | Document No. | Date | Name | Class | Subclass |
|------------------|-----------|--------------|----------|------------------|-------|----------|
| | 10 | 4,634,704 | 01/06/87 | Janssens, et al. | 514 | 253 |
| | 11 | 4,695,569 | 09/22/87 | Janssens, et al. | 514 | 258 |
| | 12 | 5,360,807 | 11/01/94 | Janssens, et al. | 514 | 318 |

FOREIGN PATENT DOCUMENTS

| Examiner Initial | | Document No. | Date | Country | Translation | |
|------------------|-----------|--------------|----------|---------|-------------|----|
| | | | | | YES | NO |
| | 13 | 0 005 318 A1 | 11/14/79 | EP | | |
| | 14 | 0 099 139 A2 | 01/25/84 | EP | | |
| | 15 | 0 144 101 A2 | 06/12/85 | EP | | |
| | 16 | 0 145 037 A2 | 06/19/85 | EP | | |
| | 17 | 0 151 824 A2 | 08/21/85 | EP | | |
| | 18 | 0 151 826 A1 | 08/21/85 | EP | | |
| | 19 | 0 232 937 A2 | 08/19/87 | EP | | |
| | 20 | 0 295 742 A1 | 12/21/88 | EP | | |
| | 21 | 0 297 661 A1 | 01/04/89 | EP | | |
| | 22 | 0 307 014 A1 | 03/15/89 | EP | | |
| | 23 | 0 747 363 A1 | 12/11/96 | EP | | |

EXAMINER**DATE CONSIDERED**

Form PTO-1449 Modified

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce
Patent and Trademark Office

Docket No.
JANS-0042

Application No.
10/817,472

Applicant
Frans E. Janssens, et al.

Filing Date
April 2, 2004

Group
Not Yet Assigned

FOREIGN PATENT DOCUMENTS

| Examiner Initial | | Document No. | Date | Country | Translation | |
|---------------------|----|----------------|----------|------------------------|-------------|----|
| | | | | | YES | NO |
| | 24 | WO 92/01687 A1 | 02/06/92 | WIPO | | |
| | 25 | WO 92/01697 A1 | 02/06/92 | WIPO | | |
| | 26 | WO 98/10764 A1 | 03/19/98 | WIPO | | |
| | 27 | WO 98/31363 A1 | 07/23/98 | WIPO | | |
| | 28 | WO 98/55120 A1 | 12/10/98 | WIPO | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| EXAMINER | | | | DATE CONSIDERED | | |